AstraZeneca (AZN) Tops Q1 EPS by 3c; Revs Light

AstraZeneca (NYSE: AZN) reported Q1 EPS of $1.81, $0.03 better than the analyst estimate of $1.78. Revenue for the quarter came in at $7.35 billion versus the consensus estimate of $7.85 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
• United Community Banks sells equipment finance unit for $1.9 billion
• Sharon AI surges premarket; New Oriental gains, Medline slips